P50 CA058236-15/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2009	2
2011	4
2012	5
2024	0

1

May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW. May KF Jr, et al. Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23. Clin Cancer Res. 2011. PMID: 21700764 Free PMC article.

2

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.

Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA. Antonarakis ES, et al. Cancer. 2012 Mar 15;118(6):1533-42. doi: 10.1002/cncr.26437. Cancer. 2012. PMID: 21960118 Free PMC article.

3

A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.

Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. Lin J, et al. Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789320 Free PMC article. Clinical Trial.

4

Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies.

Trock BJ, Brotzman MJ, Mangold LA, Bigley JW, Epstein JI, McLeod D, Klein EA, Jones JS, Wang S, McAskill T, Mehrotra J, Raghavan B, Partin AW. Trock BJ, et al. BJU Int. 2012 Jul;110(1):56-62. doi: 10.1111/j.1464-410X.2011.10718.x. Epub 2011 Nov 11. BJU Int. 2012. PMID: 22077694 Free PMC article.

5

Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.

Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. Zabransky DJ, et al. Prostate. 2012 Apr;72(5):487-98. doi: 10.1002/pros.21449. Epub 2011 Jul 11. Prostate. 2012. PMID: 21748755 Free PMC article. Clinical Trial.

6

Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.

Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM Jr, Kristal AR. Platz EA, et al. Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13. doi: 10.1158/1055-9965.EPI-09-0472. Epub 2009 Nov 3. Cancer Epidemiol Biomarkers Prev. 2009. PMID: 19887582 Free PMC article. Clinical Trial.

7

Anti-tumor effects of endogenous prostate cancer-specific CD8 T cells in a murine TCR transgenic model.

Bruno TC, Rothwell C, Grosso JF, Getnet D, Yen HR, Durham NM, Netto G, Pardoll DM, Drake CG. Bruno TC, et al. Prostate. 2012 Apr;72(5):514-22. doi: 10.1002/pros.21453. Epub 2011 Jul 14. Prostate. 2012. PMID: 21761425 Free PMC article.

8

Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Isaacs JT, et al. Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub 2012 Mar 6. Prostate. 2012. PMID: 22396319 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Results by year